Dr. Steven Hildemann, MD, PhD, appointed as Non-Executive Director

Acting in an advisory capacity, Dr. Hildemann will bring his invaluable expertise to G&L as the company continues to expand globally and pursue strategic acquisitions.

An accomplished Physician-Scientist who has served as Chief Medical Officer, Board member, and serves as adjunct professor of medicine at the University of Freiburg, Dr. Hildemann joins G&L with over three decades of experience in the healthcare sector.

Stephen Loughrey, CEO, G&L, commented:

“It is my pleasure to welcome Dr. Hildemann to the Board and I look forward to the pivotal role he will play for us here at G&L.

“Dr. Hildemann's appointment signifies a significant milestone for G&L Healthcare Advisors and underpins our commitment to our global clients as we grow our services and solutions and continue to set the standard in everything we do.

“His strategic vision and leadership will undoubtedly bolster our company's growth trajectory and enhance our ability to deliver value to our stakeholders.”

With board certification in both internal medicine and cardiology, Dr. Hildemann has extensive experience in oncology, gastroenterology, immunology, and pulmonology from a decade at University Hospitals in Munich.

He moved into the biopharmaceutical industry in 1998 where he held several leadership positions at local, regional, and global levels in Medical Affairs, Development Operations, Patient Safety, and Patient Affairs.

As the global CMO for Merck, he was instrumental in establishing and leading Global Medical Affairs (GMA) and Global Patient Safety (GPS) with multiple innovative launches. He played a significant role in co-founding a start-up joint venture focused on building a pre-commercial deep data sharing platform in Oncology (Syntropy), establishing foundational Digital Ethics.

During his tenure as EVP and Chief Medical Officer at Ipsen, Dr. Hildemann made a significant contribution to a deep corporate transformation resulting in tangible patient benefit and a major increase in enterprise value. 

He and his team orchestrated a deep transformation of Global Medical Affairs and Global Patient Safety, establishing FDA/EMA-validated GxP-quality while building data-driven insights to fortify the company's medical capabilities and deliver innovation and improved patient outcomes.